Boston Scientific Corp. BSX

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

• Zacks Investment Research 2 oct

  Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

  Boston Scientific (BSX) declined 1.46% to $42.60, underperforming the broader market which gained 0.73%. The stock has lost 7.92% over the past month. While analysts expect modest earnings growth of 1.33% YoY and revenue growth of 3.25% for the upcoming quarter, the company received a Zacks Rank #4 (Sell) rating due to a 1.3% downward revision in consensus EPS estimates over the last 30 days. However, the stock trades at a discount with a Forward P/E of 13.28 versus the industry average of 19.67.

  

• Zacks Investment Research 2 oct

  Can ISRG Offset China Weakness With Expansion in India and Japan?

  Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%.

  

• Zacks Investment Research 30 sept

  Boston Scientific's MedSurg Diversification Bolsters Growth Prospects

  Boston Scientific's MedSurg segment showed mixed Q2 2026 results with Endoscopy growing 7% and Neuromodulation up 12%, but Urology disappointed with only 1% growth due to sacral neuromodulation recovery delays and stone management portfolio gaps. The company expects flat to low-single digit Urology growth for full-year 2026 but remains confident in 2027 improvement with planned product launches. BSX stock has underperformed the industry and carries a Zacks Rank #4 (Sell) rating.

  

• GlobeNewswire Inc. 24 sept

  Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig

  ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.

  

• Zacks Investment Research 21 sept

  Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase?

  Boston Scientific plans multiple product launches through 2028 across Interventional Cardiology, EP, and CRM segments, including SEISMIQ 4CE, FARAWAVE Ultra, and PRECEDENT platforms. However, the company expects flat global EP growth in H2 2026 due to competitive pressures, with momentum expected to return in H2 2027. BSX stock has underperformed the industry over the past 12 months and carries a Zacks Rank #5 (Strong Sell) rating.